Aspen Pharmacare Holdings Limited
http://www.aspenpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aspen Pharmacare Holdings Limited
CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made
Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Trends Shaping India Pharma: Next-Gen Therapies, Adjacencies, LOE Strategies And More
The arrival of an indigenous CAR-T cell therapy, a shot at GLP-1s and Parkinson’s disease, strides into adjacencies and an “easy revenue stream” formula for products set to lose exclusivity are some of the striking developments seen playing out in India. Industry leaders, including Cipla’s CEO, share their views with Scrip on some of the key trends in the first instalment of this two-part roundup.
Asia Deal Watch: Dr Reddy’s Licenses Coya’s ALS Combo Drug
Plus deals involving Abbisko/Merck & Co., Astellas/Phenomic AI, PRISM Biolab/Lilly and WuXi Biologics/Myricx.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- Other Names / Subsidiaries
-
- Aspen Global Incorporated (AGI)
- Aspen Japan K.K.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice